• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » N-acetylcysteine Not Effective for Cannabis Use Disorder in Adults

N-acetylcysteine Not Effective for Cannabis Use Disorder in Adults

October 2, 2019
Brian Frankel, MD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Brian Frankel, MD Dr. Frankel has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Gray KM et al, Drug and Alcohol Dependence 2017;177:249–257

N-acetylcysteine (NAC) is an over-the-counter supplement related to the amino acid cysteine. In addition to its use as an antidote for acetaminophen poisoning, it has shown evidence of efficacy in some psychiatric disorders. For substance use disorders, its primary mechanism of action is the reversal of glutamate dysregulation, theoretically reducing vulnerability to relapse. A 2012 study of 116 adolescents with cannabis use disorder (CUD) found that subjects randomly assigned to 1200 mg of NAC were twice as likely to have cannabis-negative urines than those taking placebo. This most recent study attempted to replicate these findings in adults.

In this 12-week double-blind randomized controlled trial, 302 treatment-seeking adult participants diagnosed with CUD were randomized to placebo or 1200 mg NAC, both prescribed twice daily. The primary outcome was the percent likelihood of a negative urine cannabinoid test (UCT). UCTs were collected at baseline and twice weekly throughout the trial. Both groups also received a contingency management intervention (escalating cash payments to positively reinforce attendance and abstinence) and weekly medication counseling. The majority of the participants were white and male.

The results were discouraging: After 12 weeks, patients assigned to NAC submitted no more cannabis-free samples (22.3%) than those taking placebo (22.4%). However, a post-hoc analysis found that the younger participants in the trial (ages 18–21) were twice as likely to produce a negative UCT when assigned to the NAC group compared with placebo—although this finding did not reach statistical significance (p = 0.187). Though the medication was well tolerated, a major limitation of the study was poor medication adherence (73% adherence to NAC, 72% placebo), which was not problematic in the adolescent study (95% NAC, 93% placebo).

CATR’s Take
NAC does not appear to be effective for CUD in adults, though it’s possible that adolescents respond better to this supplement. Given that it is cheap and well tolerated (and that there are no effective alternatives), you might consider offering NAC to adolescents who are having difficulty cutting down their cannabis use.
Addiction Treatment
KEYWORDS addiction addiction-treatment cannabis marijuana substance-use-disorder
Brian Frankel, MD

The COMBINE Study: A Core Paper in the Treatment of AUD

More from this author
www.thecarlatreport.com
Issue Date: October 2, 2019
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Alcohol Addiction, CATR, September/October 2019
Primer: Evidence-Based Psychosocial Interventions for Substance Use Disorders
Treating Alcohol Use Disorder
Biomarkers of Alcohol Use
N-acetylcysteine Not Effective for Cannabis Use Disorder in Adults
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    (PRE-ORDER) Treating Alcohol Use Disorder—A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • Substance_Use_Sites.jpeg
    Addiction Treatment

    Supervised Drug Consumption Sites

    Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.